Preferred Label : Rosuvastatin Calcium;
MeSH definition : A HYDROXYMETHYLGLUTARYL-COA-REDUCTASE INHIBITOR, or statin, that reduces the plasma
concentrations of LDL-CHOLESTEROL; APOLIPOPROTEIN B, and TRIGLYCERIDES while increasing
HDL-CHOLESTEROL levels in patients with HYPERCHOLESTEROLEMIA and those at risk for
CARDIOVASCULAR DISEASES.;
MeSH synonym : Calcium, Rosuvastatin;
MeSH Hyperonym : rosuvastatin;
MeSH hyponym : ZD4522; crestor; ZD 4522;
MeSH Related Number : 287714-41-4 (Rosuvastatin); 413KH5ZJ73;
Wikipedia link : https://en.wikipedia.org/wiki/Rosuvastatin;
Is substance : O;
UNII : 83MVU38M7Q;
Origin ID : D000068718;
UMLS CUI : C1101751;
ATC code(s)
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
Pharmacological action(s)
Record concept(s)
Related MeSH Supplementary Concept(s)
See also
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to NTBT
A HYDROXYMETHYLGLUTARYL-COA-REDUCTASE INHIBITOR, or statin, that reduces the plasma
concentrations of LDL-CHOLESTEROL; APOLIPOPROTEIN B, and TRIGLYCERIDES while increasing
HDL-CHOLESTEROL levels in patients with HYPERCHOLESTEROLEMIA and those at risk for
CARDIOVASCULAR DISEASES.
https://ansm.sante.fr/actualites/decision-dautorisation-dimportation-parallele-accordee-le-21-03-2024-suvreza-20-mg-10-mg-comprime-pellicule
2024
false
false
false
France
French
drug information
legislation, pharmacy
drug combinations
Ezetimibe
Rosuvastatin Calcium
rosuvastatin and ezetimibe
spain
---
https://www.has-sante.fr/jcms/p_3471816/fr/suvreza-rosuvastatine-calcique/ezetimibe-hypercholesterolemie
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
drug combinations
Ezetimibe
Rosuvastatin Calcium
anticholesteremic agents
hydroxymethylglutaryl-coa reductase inhibitors
administration, oral
rosuvastatin and ezetimibe
adult
hypercholesterolemia
Primary hypercholesterolemia (disorder)
Familial hypercholesterolemia - heterozygous (disorder)
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3315455/fr/zelfusor-rosuvastatine
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
capsules
Product containing only rosuvastatin in oral dose form (medicinal product form)
adult
child
adolescent
cardiovascular diseases
hypercholesterolemia
hydroxymethylglutaryl-coa reductase inhibitors
evaluation of the transparency committee
Rosuvastatin Calcium
---
https://www.has-sante.fr/jcms/c_2913804/fr/crestor
2020
false
false
false
France
rosuvastatin
hyperlipoproteinemia type ii
child
adolescent
hydroxymethylglutaryl-coa reductase inhibitors
treatment outcome
Familial hypercholesterolemia - heterozygous (disorder)
Familial hypercholesterolemia - homozygous (disorder)
administration, oral
evaluation of the transparency committee
Rosuvastatin Calcium
---
https://www.has-sante.fr/portail/jcms/c_2972299/fr/twicor
2019
false
false
false
France
French
drug combinations
rosuvastatin
Ezetimibe
treatment outcome
insurance, health, reimbursement
administration, oral
hydroxymethylglutaryl-coa reductase inhibitors
anticholesteremic agents
hypercholesterolemia
evaluation of the transparency committee
Rosuvastatin Calcium
---
https://www.has-sante.fr/jcms/p_3107047/fr/suvreza
2019
false
false
false
France
rosuvastatin and ezetimibe
drug combinations
adult
Rosuvastatin Calcium
Ezetimibe
treatment outcome
administration, oral
hydroxymethylglutaryl-coa reductase inhibitors
anticholesteremic agents
hypercholesterolemia
Familial hypercholesterolemia - homozygous (disorder)
Primary hypercholesterolemia (disorder)
evaluation of the transparency committee
---
https://www.has-sante.fr/portail/jcms/c_2912397/fr/crestor
2019
true
false
France
French
hypercholesterolemia
adult
adolescent
child
hyperlipoproteinemia type ii
Rosuvastatin Calcium
Homozygous familial hypercholesterolemia
statine
amino acids
administration, oral
hydroxymethylglutaryl-coa reductase inhibitors
rosuvastatin
insurance, health, reimbursement
cardiovascular diseases
risk
treatment outcome
evaluation of the transparency committee
---
https://www.has-sante.fr/portail/jcms/c_2913804/fr/crestor
2019
false
true
false
false
France
Rosuvastatin Calcium
administration, oral
rosuvastatin
child
adolescent
Familial hypercholesterolemia - heterozygous (disorder)
Familial hypercholesterolemia - homozygous (disorder)
treatment outcome
insurance, health, reimbursement
hydroxymethylglutaryl-coa reductase inhibitors
hyperlipoproteinemia type ii
amino acids
evaluation of the transparency committee
Rosuvastatin Calcium
crestor
---
https://www.has-sante.fr/portail/jcms/c_2863024/fr/liporosa
2018
false
false
false
false
France
French
evaluation of the transparency committee
administration, oral
drug combinations
treatment outcome
insurance, health, reimbursement
rosuvastatin
rosuvastatin
Hydroxymethylglutaryl-CoA reductase inhibitors
Hydroxymethylglutaryl-CoA reductase inhibitors
rosuvastatin and ezetimibe
Ezetimibe
Ezetimibe
anticholesteremic agents
anticholesteremic agents
hypercholesterolemia
Primary hypercholesterolemia (disorder)
Rosuvastatin Calcium
Rosuvastatin Calcium
hydroxymethylglutaryl-coa reductase inhibitors
hydroxymethylglutaryl-coa reductase inhibitors
---
https://minerva-ebp.be/FR/Article/2084
2017
false
false
false
Belgium
French
critical appraisal or critical reading
cardiovascular risk
cardiovascular diseases
risk
hydroxymethylglutaryl-coa reductase inhibitors
Rosuvastatin Calcium
adult
aged
treatment outcome
---
http://www.has-sante.fr/portail/jcms/c_2011666/fr/crestor
2015
true
France
French
child
hyperlipoproteinemia type ii
Rosuvastatin Calcium
administration, oral
insurance, health, reimbursement
anticholesteremic agents
hydroxymethylglutaryl-coa reductase inhibitors
rosuvastatin
treatment outcome
evaluation of the transparency committee
---
http://circulaire.legifrance.gouv.fr/index.php?action=afficherCirculaire&hit=1&r=39060
http://circulaire.legifrance.gouv.fr/pdf/2014/12/cir_39060.pdf
2015
false
false
false
France
French
legislation, pharmacy
insurance, health, reimbursement
rosuvastatin
hydroxymethylglutaryl-coa reductase inhibitors
ezetimibe
legislation
anticholesteremic agents
forms
simvastatin and ezetimibe
Ezetimibe, Simvastatin Drug Combination
Ezetimibe
Rosuvastatin Calcium
---
https://assurance-maladie.ameli.fr/etudes-et-donnees/2014-efficacite-comparee-rosuvastatine-simvastatine
2014
France
technical report
simvastatin
efficiency
simvastatin
Rosuvastatin Calcium
primary prevention
rosuvastatin
principal
---
http://www.has-sante.fr/portail/jcms/c_1020687/crestor-rosuvastatine-statine
http://www.has-sante.fr/portail/jcms/c_1735631/fr/crestor
http://www.has-sante.fr/portail/jcms/c_1761180/fr/crestor
2014
false
France
French
hypercholesterolemia
adult
adolescent
child
hyperlipoproteinemia type ii
Rosuvastatin Calcium
administration, oral
hydroxymethylglutaryl-coa reductase inhibitors
rosuvastatin
insurance, health, reimbursement
cardiovascular diseases
risk
treatment outcome
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/r_1439693
2012
true
France
French
Atorvastatin
Rosuvastatin Calcium
cardiovascular diseases
Cost-Benefit analysis
hydroxymethylglutaryl-coa reductase inhibitors
hmg coa reductase inhibitors
risk factors
cholesterol, LDL
hypercholesterolemia
simvastatin
anticholesteremic agents
pravastatin
treatment outcome
fatty acids, monounsaturated
indoles
guidelines for drug use
Fluvastatin
---
http://www.lecrat.eu/?s=Rosuvastatine
2011
false
France
French
Rosuvastatin Calcium
pregnancy
hydroxymethylglutaryl-coa reductase inhibitors
rosuvastatin
drug information
---
http://www.has-sante.fr/portail/jcms/c_996905/crestor
http://www.has-sante.fr/portail/jcms/c_997109/crestor-ct-8369
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-12/crestor_ct_8369.pdf
2010
false
France
French
English
Rosuvastatin Calcium
Rosuvastatin Calcium
risk factors
rosuvastatin
administration, oral
insurance, health, reimbursement
hydroxymethylglutaryl-coa reductase inhibitors
hydroxymethylglutaryl-coa reductase inhibitors
cardiovascular diseases
treatment outcome
clinical trials, phase iii as topic
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_1020699/crestor
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-01/synthese_davis_crestor_enfant-ct-8367.pdf
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-01/crestor_enfant_-_ct-8367.pdf
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-12/crestor_ct_8367.pdf
2010
false
France
French
Rosuvastatin Calcium
Rosuvastatin Calcium
adult
adolescent
child
administration, oral
rosuvastatin
insurance, health, reimbursement
hyperlipoproteinemia type ii
dyslipidemias
hydroxymethylglutaryl-coa reductase inhibitors
hydroxymethylglutaryl-coa reductase inhibitors
evaluation of the transparency committee
treatment outcome
clinical trials, phase iii as topic
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-01/synthese_davis_crestor_enfant-ct-8367.pdf
http://www.has-sante.fr/portail/jcms/c_1020685/crestor-rosuvastatine-statine
2010
false
France
French
Rosuvastatin Calcium
mixed dyslipidemia
hyperlipoproteinemia type IIa
treatment outcome
insurance, health, reimbursement
administration, oral
child
adolescent
hypercholesterolemia
hydroxymethylglutaryl-coa reductase inhibitors
rosuvastatin
dyslipidemias
guidelines for drug use
evaluation of the transparency committee
hyperlipoproteinemia type ii
---
https://minerva-ebp.be/fr/article/287
2010
false
false
minerva-ebm.be
Belgium
Dutch
French
Rosuvastatin Calcium
C-reactive protein
stroke
incidence
follow-up studies
risk factors
rosuvastatin
hydroxymethylglutaryl-coa reductase inhibitors
cholesterol, LDL
stroke
treatment outcome
critical appraisal or critical reading
---
https://minerva-ebp.be/fr/article/406
2009
false
false
minerva-ebm.be
Belgium
French
cardiovascular risk
Rosuvastatin Calcium
C-reactive protein
hydroxymethylglutaryl-coa reductase inhibitors
cardiovascular diseases
rosuvastatin
critical appraisal or critical reading
---
https://minerva-ebp.be/fr/article/452
2009
false
minerva-ebm.be
Belgium
French
Rosuvastatin Calcium
hydroxymethylglutaryl-coa reductase inhibitors
heart failure
critical appraisal or critical reading
---
http://www.has-sante.fr/portail/jcms/c_794885/crestor
http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-05/crestor_-_ct-5927.pdf
2009
false
France
French
Rosuvastatin Calcium
administration, oral
insurance, health, reimbursement
anticholesteremic agents
hydroxymethylglutaryl-coa reductase inhibitors
rosuvastatin
treatment outcome
evaluation of the transparency committee
---
http://www.cbip.be/Folia/Index.cfm?FoliaWelk=F36F02D
2009
false
Belgium
French
Dutch
Rosuvastatin Calcium
heart failure
chronic disease
heart failure
eicosapentaenoic acid
hospitalization
randomized controlled trials as topic
treatment outcome
docosahexaenoic acids
rosuvastatin
journal article
drug information
---
http://www.cbip.be/Folia/Index.cfm?FoliaWelk=F36F01E
2009
false
Belgium
French
Dutch
Rosuvastatin Calcium
primary prevention
cardiovascular diseases
hydroxymethylglutaryl-coa reductase inhibitors
follow-up studies
cholesterol, LDL
C-reactive protein
treatment outcome
rosuvastatin
drug information
journal article
---
https://rmlg.uliege.be/article/1409
2006
false
Belgium
French
Rosuvastatin Calcium
clinical trials as topic
coronary artery disease
coronary artery disease
cholesterol, HDL
cholesterol, LDL
hydroxymethylglutaryl-coa reductase inhibitors
middle aged
ultrasonography, interventional
rosuvastatin
journal article
---
https://rmlg.uliege.be/article/1008
2004
false
Belgium
French
Primary hypercholesterolemia (disorder)
Rosuvastatin Calcium
Rosuvastatin Calcium
mixed dyslipidemia
hypercholesterolemia
hydroxymethylglutaryl-coa reductase inhibitors
treatment outcome
dose-response relationship, drug
dyslipidemias
cholesterol, LDL
triglycerides
hydroxymethylglutaryl-coa reductase inhibitors
rosuvastatin
journal article
drug information
comparative study
---
https://www.cadth.ca/sites/default/files/pdf/159_rosuvastatin_cetap_e.pdf
https://www.cadth.ca/sites/default/files/pdf/159_rosuvastatin_cetap_f.pdf
2001
false
Canada
French
English
Rosuvastatin Calcium
hydroxymethylglutaryl-coa reductase inhibitors
hypercholesterolemia
treatment outcome
canada
Evidence-Based medicine
rosuvastatin
drug evaluation
---